Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Banzel in Lennox-Gastaut Syndrome (Long-term Extension)
NCT01151540Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Nov 2010
- Primary completion
- Aug 2013
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rufinamide in Lennox-Gastaut syndrome (LGS), sponsored by Eisai Co., Ltd. Primary endpoint: Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Rufinamide. Started Nov 2010; status: completed.
02
Drugs
rufinamide
03
Conditions
Lennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on NCT01151540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01151540.